Tirzepatide
SURPASS-T1D-1
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 905
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Tirzepatide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 3 | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 4 | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.